This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.
Patrick Vallance appointed to GSK executive leadership team
Issued: Tuesday 11 May 2010, London UK
GlaxoSmithKline (GSK) today announced the appointment of Patrick Vallance, as Senior Vice President, Medicines Discovery and Development and as a member of the company’s Corporate Executive Team both with effect from 1st July 2010.
Andrew Witty, Chief Executive Officer, GSK commented: “Patrick has a deep level of scientific and medical acumen, which coupled with his proven management skills, mean he is well placed to bring further R&D perspective to GSK’s leadership team. This appointment aligns with the company’s drive to increase R&D productivity and deliver more products of value. I look forward to working with Patrick in his new role and welcome him to the executive team.”
Prior to joining GSK in 2006, Patrick was a clinical academic and led the Division of Medicine at UCL. He has over 20 years of experience of clinical medicine and has an international reputation as a vascular biologist and clinician scientist. He was elected to the Academy of Medical Sciences in 1999, and subsequently became its Registrar before leaving to join GSK.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
|
GlaxoSmithKline Enquiries:
|
|
|
|
UK Media enquiries:
|
Philip Thomson
|
(020) 8047 5502
|
|
|
Claire Brough
|
(020) 8047 5502
|
|
|
Stephen Rea
|
(020) 8047 5502
|
|
|
Alexandra Harrison
|
(020) 8047 5502
|
|
|
Jo Revill
|
(020) 8047 5502
|
|
|
|
|
|
US Media enquiries:
|
Nancy Pekarek
|
(919) 483 2839
|
|
|
Mary Anne Rhyne
|
(919) 483 2839
|
|
|
Kevin Colgan
|
(919) 483 2839
|
|
|
Sarah Alspach
|
(919) 483 2839
|
|
|
|
|
|
European Analyst/Investor enquiries:
|
David Mawdsley
|
(020) 8047 5564
|
|
|
Sally Ferguson
|
(020) 8047 5543
|
|
|
Gary Davies
|
(020) 8047 5503
|
|
|
|
|
|
US Analyst/ Investor enquiries:
|
Tom Curry
|
(215) 751 5419
|
|
|
Jen Hill Baxter
|
(215) 751 7002
|
Subscribe to press releases
Printer-friendly version
Send by email